Indication

Metastatic castration-sensitive prostate cancer

Metastatic castration-sensitive prostate cancer is an advanced stage of malignancy originating in the male prostate gland that has disseminated beyond regional pelvic lymph nodes to distant sites, most commonly the skeleton, non-regional lymph nodes, or visceral organs. Read more about Metastatic castration-sensitive prostate cancer

31 drugs 28 manufacturers

Advertisement

Drugs that treat it

Common Metastatic castration-sensitive prostate cancer therapies.

Showing 1–9 of 31 drugs

ZYTIGA (abiraterone acetate)

ANTI-ANDROGEN - ANDROGEN SYNTHESIS INHIBITORS·METASTATIC CASTRATION-RESISTANT PROSTATE CANCER·+1
JANSSEN BIOTECH, Inc.

ERLEADA (apalutamide)

ANTIANDROGEN·METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER·+1
JANSSEN BIOTECH, Inc.

ABIRATERONE ACETATE

ANTI-ANDROGEN - ANDROGEN SYNTHESIS INHIBITORS·METASTATIC CASTRATION-RESISTANT PROSTATE CANCER·+1
Mylan Pharmaceuticals

ABIRATERONE ACETATE

ANTI-ANDROGEN - ANDROGEN SYNTHESIS INHIBITORS·METASTATIC CASTRATION-RESISTANT PROSTATE CANCER·+1
APOTEX CORP

ABIRATERONE ACETATE

ANTI-ANDROGEN - ANDROGEN SYNTHESIS INHIBITORS·METASTATIC CASTRATION-RESISTANT PROSTATE CANCER·+1
TEVA USA

ABIRATERONE ACETATE

ANTI-ANDROGEN - ANDROGEN SYNTHESIS INHIBITORS·METASTATIC CASTRATION-RESISTANT PROSTATE CANCER·+1
Amneal Pharmaceuticals

ABIRATERONE ACETATE

ANTI-ANDROGEN - ANDROGEN SYNTHESIS INHIBITORS·METASTATIC CASTRATION-RESISTANT PROSTATE CANCER·+1
Hikma Pharmaceuticals USA
Filter & compare in the drug finder →Opens the drug finder with Metastatic castration-sensitive prostate cancer preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Metastatic castration-sensitive prostate cancer.

Metastatic castration-sensitive prostate cancer is an advanced stage of malignancy originating in the male prostate gland that has disseminated beyond regional pelvic lymph nodes to distant sites, most commonly the skeleton, non-regional lymph nodes, or visceral organs.

The defining pathophysiologic feature of this clinical state is the continued dependence of the metastatic tumor cells on androgen receptor signaling pathways for survival and proliferation.

Consequently, patients remain functionally responsive to androgen suppression, whether they are treatment-naive or previously exposed to medical or surgical castration without having developed disease progression at castrate levels of serum testosterone.

Personalize your experience

Follow Metastatic castration-sensitive prostate cancer and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it